Innovent Biologics Unveils Promising Preclinical Results for IBI3011 and IBI3034 at 2025 ACR Meeting

Reuters

11/05

Innovent Biologics Unveils Promising Preclinical Results for IBI3011 and IBI3034 at 2025 ACR Meeting

Innovent Biologics Inc. announced the presentation of new preclinical study results for two investigational therapies, IBI3011 and IBI3034, at the 2025 American College of Rheumatology $(ACR)$ Annual Meeting. IBI3011 is a humanized monoclonal antibody targeting IL-1RAP, designed to inhibit inflammation driven by IL1α, IL1β, and IL36, and demonstrated efficacy in animal models of gout and arthritis as well as favorable pharmacokinetic and safety profiles in monkeys. A high-concentration formulation of IBI3011 has been developed to allow subcutaneous administration, and its IND application has been approved by China's National Medical Products Administration (NMPA) for acute gouty arthritis. IBI3034, a TACI/BCMA chimeric fusion protein, is currently undergoing IND-enabling studies for B cell-mediated autoimmune diseases. The results were showcased as poster presentations at the ACR 2025 conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN14968) on November 05, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581659799"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581659799\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581659799?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 08:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581659799","market":"fut","top_or_hot":-1,"title":"Innovent Biologics Unveils Promising Preclinical Results for IBI3011 and IBI3034 at 2025 ACR Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent Biologics Unveils Promising Preclinical Results for IBI3011 and IBI3034 at 2025 ACR Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> announced the presentation of new preclinical study results for two investigational therapies, IBI3011 and IBI3034, at the 2025 American College of Rheumatology <a href=\"https://laohu8.com/S/ACR\">$(ACR)$</a> Annual Meeting. IBI3011 is a humanized monoclonal antibody targeting IL-1RAP, designed to inhibit inflammation driven by IL1α, IL1β, and IL36, and demonstrated efficacy in animal models of gout and arthritis as well as favorable pharmacokinetic and safety profiles in monkeys. A high-concentration formulation of IBI3011 has been developed to allow subcutaneous administration, and its IND application has been approved by China's National Medical Products Administration (NMPA) for acute gouty arthritis. IBI3034, a TACI/BCMA chimeric fusion protein, is currently undergoing IND-enabling studies for B cell-mediated autoimmune diseases. The results were showcased as poster presentations at the ACR 2025 conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN14968) on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics Unveils Promising Preclinical Results for IBI3011 and IBI3034 at 2025 ACR Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics Unveils Promising Preclinical Results for IBI3011 and IBI3034 at 2025 ACR Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-05 08:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent Biologics Unveils Promising Preclinical Results for IBI3011 and IBI3034 at 2025 ACR Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> announced the presentation of new preclinical study results for two investigational therapies, IBI3011 and IBI3034, at the 2025 American College of Rheumatology <a href=\"https://laohu8.com/S/ACR\">$(ACR)$</a> Annual Meeting. IBI3011 is a humanized monoclonal antibody targeting IL-1RAP, designed to inhibit inflammation driven by IL1α, IL1β, and IL36, and demonstrated efficacy in animal models of gout and arthritis as well as favorable pharmacokinetic and safety profiles in monkeys. A high-concentration formulation of IBI3011 has been developed to allow subcutaneous administration, and its IND application has been approved by China's National Medical Products Administration (NMPA) for acute gouty arthritis. IBI3034, a TACI/BCMA chimeric fusion protein, is currently undergoing IND-enabling studies for B cell-mediated autoimmune diseases. The results were showcased as poster presentations at the ACR 2025 conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN14968) on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2097828557.USD","symbol_name":"AZ EQUITY CHINA \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL3TBBFX:1","article_id":"2581659799","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581659799","pubTimestamp":1762300845,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Innovent Biologics Inc. announced the presentation of new preclinical study results for two investigational therapies, IBI3011 and IBI3034, at the 2025 American College of Rheumatology  Annual Meeting. IBI3011 is a humanized monoclonal antibody targeting IL-1RAP, designed to inhibit inflammation driven by IL1α, IL1β, and IL36, and demonstrated efficacy in animal models of gout and arthritis as well as favorable pharmacokinetic and safety profiles in monkeys. A high-concentration formulation of IBI3011 has been developed to allow subcutaneous administration, and its IND application has been approved by China's National Medical Products Administration  for acute gouty arthritis. IBI3034, a TACI/BCMA chimeric fusion protein, is currently undergoing IND-enabling studies for B cell-mediated autoimmune diseases. The results were showcased as poster presentations at the ACR 2025 conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","01801":"信达生物","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","01911":"华兴资本控股","BK1583":"高瓴概念","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","BK1589":"北水核心资产","BK1161":"生物科技","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","BK1147":"投资银行业与经纪业"},"translate_title":"信达生物在2025年ACR会议上公布IBI3011和IBI3034有希望的临床前结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":0.9,"01911":0.9},"content_text":"Innovent Biologics Unveils Promising Preclinical Results for IBI3011 and IBI3034 at 2025 ACR Meeting\n    \n\nInnovent Biologics Inc. announced the presentation of new preclinical study results for two investigational therapies, IBI3011 and IBI3034, at the 2025 American College of Rheumatology $(ACR)$ Annual Meeting. IBI3011 is a humanized monoclonal antibody targeting IL-1RAP, designed to inhibit inflammation driven by IL1α, IL1β, and IL36, and demonstrated efficacy in animal models of gout and arthritis as well as favorable pharmacokinetic and safety profiles in monkeys. A high-concentration formulation of IBI3011 has been developed to allow subcutaneous administration, and its IND application has been approved by China's National Medical Products Administration (NMPA) for acute gouty arthritis. IBI3034, a TACI/BCMA chimeric fusion protein, is currently undergoing IND-enabling studies for B cell-mediated autoimmune diseases. The results were showcased as poster presentations at the ACR 2025 conference.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN14968) on November 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}